
AimMax Therapeutics: Pioneering pharmaceutical research and development.
AimMax Therapeutics, founded with a mission to maximize global health through innovative science and passionate research, focuses on the research and development of pharmaceuticals across various stages. The company aims to address unmet medical needs by developing cutting-edge therapies that improve patient outcomes. Their market focus spans multiple therapeutic areas, including but not limited to oncology, neurology, and infectious diseases.
Notable figures associated with AimMax Therapeutics include leading scientists and industry experts who drive their research initiatives. The company has garnered attention from prominent investors in the pharmaceutical sector, enabling significant advancements in their pipeline. Key achievements include successful preclinical trials and strategic partnerships with major healthcare institutions. AimMax Therapeutics is making a substantial impact on global health by pushing the boundaries of medical science.

Aria Pharmaceuticals

Chase Therapeutics

Theracos
theracos.com

Guardian Therapeutics

Emergo Therapeutics

Aristea Therapeutics

Applied Therapeutics

AffaMed Therapeutics
affamed.com

Maxona Pharmaceuticals
maxonapharm.com

Antios Therapeutics

Akttyva Therapeutics
akttyva.com

Eikon Therapeutics
eikontx.com

Escient Pharmaceuticals
Athenen Therapeutics

Dose Therapeutics
Companies similar to AimMax Therapeutics include Aria Pharmaceuticals, Chase Therapeutics, Theracos and Guardian Therapeutics.
AimMax Therapeutics was founded in 2017.
AimMax Therapeutics' headquarters is located in Durham, NC, US.
AimMax Therapeutics' most recent funding round was for $75k (USD) in September 2022.
As of Sep 22, 2022, AimMax Therapeutics has raised a total of $75k (USD).
AimMax Therapeutics has 7 employees as of Feb 5, 2024.